GSK could still cause problems for the British firm: UBS. GlaxoSmithKline (GSK) saw its shares jump more than 6% after the ...

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according ...

By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a ...

GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

The agreement, announced on Wednesday, was far lower than some analyst estimates, including JP Morgan's projection of $3.5 ...

The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...

The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...

GSK plc (GSK, GSK.L) announced that it has reached agreements with 10 plaintiff firms representing approximately 93% (around 80,000) ...